Randomized Double-blind Placebo-controlled Proof-of-concept Trial of Resveratrol for Outpatient Treatment of Mild Coronavirus Disease (COVID-19)
Marvin R McCreary, Patrick M Schnell, Dale A Rhoda, Marvin R McCreary, Patrick M Schnell, Dale A Rhoda
Abstract
Resveratrol is a polyphenol that has been well studied and has demonstrated anti-viral and anti-inflammatory properties that might mitigate the effects of COVID-19. Outpatients (N=105) were recruited from central Ohio in late 2020. Participants were randomly assigned to receive placebo or resveratrol. Both groups received a single dose of Vitamin D3 which was used as an adjunct. The primary outcome measure was hospitalization within 21 days of symptom onset; secondary measures were ER visits, incidence of pneumonia and pulmonary embolism. Five patients chose not to participate after randomization. Twenty-one day outcome was determined of all one hundred participants (mean [SD] age 55.6 [8.8] years; 61% female) (or their surrogates). There were no clinically significant adverse events attributed to resveratrol. Outpatients in this phase 2 study treated with resveratrol had a lower incidence compared to placebo of: hospitalization (2% vs. 6%, RR 0.33, 95% CI 0.04-3.10), COVID-related ER visits (8% vs. 14%, RR 0.57, 95% CI 0.18-1.83), and pneumonia (8% vs. 16%, RR 0.5, 95% CI 0.16-1.55). One patient (2%) in each group developed pulmonary embolism (RR 1.00, 95% CI: 0.06-15.55). This underpowered study was limited by small sample size and low incidence of primary adverse events. A larger trial could determine efficacy. TRIAL REGISTRATIONS: ClinicalTrials.gov NCT04400890 26/05/2020; FDA IND #150033 05/05/2020.
Conflict of interest statement
Conflicts of Interest:
The authors declare no conflict of interest.
Figures
References
- Tomé-Carneiro J. et al.Resveratrol and clinical trials: The crossroad from in vitro studies to human evidence. Curr. Pharm. Design, 19, 6064–6093 (2013).
- Abba Y., Hassim H., Hamzah H. & Noordin M. M. Antiviral activity of resveratrol against human and animal viruses. Advances in Virology 2015, (2015).
- Li M. et novo production of resveratrol from glucose or ethanol by engineered Saccharomyces cerevisiae. Metab. Eng, 32, 1–11 (2015).
- Wahedi H. M., Ahmad S. & Abbasi S. W. Stilbene-based natural compounds as promising drug candidates against COVID-19. Journal of Biomolecular Structure and Dynamics, 39, 1–10 (2020).
- Pandey P. et al.Targeting SARS-CoV-2 spike protein of COVID-19 with naturally occurring phytochemicals: an in silico study for drug development. null 1–11(2020) doi:10.1080/07391102.2020.1796811.
- Ranjbar A., Jamshidi M. & Torabi S. Molecular modelling of the antiviral action of Resveratrol derivatives against the activity of two novel SARS CoV-2 and 2019-nCoV receptors.Eur Rev Med Pharmacol Sc 7834–7844(2020).
- Mishra A., Pathak Y. & Tripathi V. Natural compounds as potential inhibitors of novel coronavirus (COVID-19) main protease: An in silico study. Research Square Preprint, 10.21203/-22839/v2 (2020).
- Shin D., Mukherjee R. & Grewe D. & et al. Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity. Nature, 587, 657–622 (2020).
- Rathnayake A. et al. & 3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV-infected mice.Science Translational Medicine,12 (2020).
- El-Aziz N. M. A., Shehata M. G., Awad O. M. E. & El-Sohaimy S. A. Inhibition of COVID-19 RNA-Dependent RNA polymerase by natural bioactive compounds: Molecular docking analysis. Research Square Preprint, 10.21203/-25850/v1 (2020).
- Maity B., Bora M. & Sur D. An effect of combination of resveratrol with vitamin D3 on modulation of proinflammatory cytokines in diabetic nephropathy induces rat. Oriental Pharmacy and Experimental Medicine, 18, 127–138 (2018).
- Estrov Z., Shishodia S. & Faderl S. & et al. Resveratrol blocks interleukin-1 beta-induced activation of the nuclear transcription factor NF-kappaB, inhibits proliferation, causes S-phase arrest, and induces apoptosis of acute myeloid leukemia cells., 102, 987–995 (2003).
- Zhu J., Yong W. & Wu X. Anti-inflammatory effect of resveratrol on TNF-alpha-induced MCP-1 expression in adipocytes. Biochemical and Biophysical Research Communications, 369, 471–477 (2008).
- Sun J. et al.Suppression of TLR4 activation by resveratrol is associated with STAT3 and Akt inhibition in oxidized low-density lipoprotein-activated platelets. European Journal of Pharmacology, 836, 1–10(2018).
- Shigematsu S. et al.Resveratrol, a red wine constituent polyphenol, prevents superoxide-dependent inflammatory responses induced by ischemia/reperfusion, platelet-activating factor, or oxidants. Free Radical Biology and Medicine, 34, 810–817 (2003).
- Xia N., Förstermann U. & Li H. Resveratrol and endothelial nitric oxide., 19, 16102–16121 (2014).
- Åkerström S. et al.Nitric oxide inhibits the replication cycle of severe acute respiratory syndrome coronavirus. Journal of Virology, 79, 1966–1969 (2005).
- Åkerström S., Gunalan V., Keng C. T., Tan Y. J. & Mirazimi A. Dual effect of nitric oxide on SARS-CoV replication: Viral RNA production and palmitoylation of the S protein are affected., 395, 1–9 (2009).
- Ren X. et al.Resveratrol inhibits NF-kB signaling through suppression of p65 and IkappaB kinase activities., 68, 689 (2013).
- Xuzhu G., Komai-Koma M. & Leung B. & et al. Resveratrol modulates murine collagen-induced arthritis by inhibiting Th17 and B-cell function. Ann Rheum Dis, 71, 129–135 (2021).
- Polonikov A. Endogenous deficiency of glutathione as the most likely cause of serious manifestations and death in COVID-19 patients. ACS Infectious Diseases, 6, 1558–1562 (2020).
- Kode A. et al.Resveratrol induces glutathione synthesis by activation of Nrf2 and protects against cigarette smoke-mediated oxidative stress in human lung epithelial cells. Am J Physiol Lung Cell Mol Physiol, 294, L478–L488 (2008).
- Horowitz R. I., Freeman P. R. & Bruzzese J. Efficacy of glutathione therapy in relieving dyspnea associated with COVID-19 pneumonia: A report of 2 cases. Respiratory Medicine Case Reports, 30, 101063 (2020).
- Kuba K. et al.A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nature Medicine, 11, 875–879 (2005).
- Mehta P. et al.COVID-19: consider cytokine storm syndromes and immunosuppression. The Lancet, 395, 1033–1034 (2020).
- Nicholls J., Peiris M. & Good, A. C. E. bad ACE do battle in lung injury, SARS. Nature Medicine, 11, 821–822 (2005).
- Gu H. et al.Angiotensin-converting enzyme 2 inhibits lung injury induced by respiratory syncytial virus. Sci. Rep, 6, 19840–19840 (2016).
- Yan T., Xiao R. & Lin G. Angiotensin-converting enzyme 2 in severe acute respiratory syndrome coronavirus and SARS-CoV-2: A double-edged sword? The FASEB Journal, 34, 6017–6026 (2020).
- Moran C. S. et al.Resveratrol inhibits growth of experimental abdominal aortic aneurysm associated with upregulation of angiotensin-converting enzyme 2. Arteriosclerosis, Thrombosis, and Vascular Biology, 37, 2195–2203 (2017).
- Imai Y. et al.Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature, 436, 112–116 (2005).
- Horne J. R. & Vohl M. C. Biological plausibility for interactions between dietary fat, resveratrol, ACE2, and SARS-CoV illness severity. Am J Physiol Endocrinol Metab, 318, E830–E833 (2020).
- Magrone T., Magrone M. & Jirillo E. Focus on receptors for coronaviruses with special reference to angiotensin-converting enzyme 2 as a potential drug target - a perspective. Endocrine, Metabolic & Immune Disorders-Drug Targets, 20, 1–11 (2020).
- Lin S. C. et al.Effective inhibition of MERS-CoV infection by resveratrol. BMC Infectious Diseases, 17, 144 (2017).
- Olejnik J., Hume A. J. & Mühlberger E. Toll-like receptor 4 in acute viral infection: Too much of a good thing.PLOS Pathogens 14, (2018).
- Conti P. et al.Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by COVID-19: anti-inflammatory strategies. Journal of Biological Regulators and Homeostatic Agents 34, (2020).
- Patterson B. K. et al.Disruption of the CCL5/RANTES-CCR5 Pathway Restores Immune Homeostasis and Reduces Plasma Viral Load in Critical COVID-19. (2020).
- Wang W. et al.Up-regulation of IL-6 and TNF-α induced by SARS-coronavirus spike protein in murine macrophages via NF-κB pathway. Virus Res, 128, 1–8 (2007).
- Zhu X., Lei X. & Dong W. Resveratrol as a potential therapeutic drug for respiratory system diseases. Drug Design Development and Therapy, 11, 3591–3598 (2017).
- Culpitt S. V. et al.Inhibition by red wine extract, resveratrol, of cytokine release by alveolar macrophages in COPD., 58, 942–946 (2003).
- DeDiego M. L. et al.Inhibition of NF-κB-mediated inflammation in severe acute respiratory syndrome coronavirus-infected mice increases survival. Journal of Virology, 88, 913–924 (2014).
- Alghetaa H. et al.Resveratrol protects mice against SEB-induced acute lung injury and mortality by miR-193a modulation that targets TGF-β signalling. Journal of Cellular and Molecular Medicine, 22, 2644–2655 (2018).
- Jiang L. et al.Resveratrol ameliorates LPS-induced acute lung injury via NLRP3 inflammasome modulation. Biomed. Pharmacother, 84, 130–138 (2016).
- Chen H., Bai C. & Wang X. The value of the lipopolysaccharide-induced acute lung injury model in respiratory medicine. Expert Review of Respiratory Medicine, 4, 773–783 (2010).
- Shah A. Novel coronavirus-induced NLRP3 inflammasome activation: A potential drug target in the treatment of COVID-19.Frontiers in Immunology 11, (2020).
- Wang J. Z., Zhang R. Y. & Bai J. An anti-oxidative therapy for ameliorating cardiac injuries of critically ill COVID-19-infected patients. International Journal of Cardiology, 312, 137–138 (2020).
- Zhao X. et al.Antiviral effect of resveratrol in piglets infected with virulent pseudorabies virus. Viruses, 10, 457 (2018).
- Fagone P. et al.Transcriptional landscape of SARS-CoV-2 infection dismantles pathogenic pathways activated by the virus, proposes unique sex-specific differences and predicts tailored therapeutic strategies. Autoimmun. rev, 19, 102571–102571 (2020).
- Palamara A. T. et al.Inhibition of influenza a virus replication by resveratrol. The Journal of Infectious Diseases, 191, 1719–1729 (2005).
- Zang N. et al.Resveratrol-mediated gamma interferon reduction prevents airway inflammation and airway hyperresponsiveness in respiratory syncytial virus-infected immunocompromised mice. Journal of Virology, 85, 13061–13068 (2011).
- Grant W. et al.Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths. Nutrients, 12, 988 (2020).
- Aslan M. T., Aslan Ä. Ã. & Özdemir Ã. Is Vitamin D One of the Key Elements in COVID-19 Days? J Nutr Health Aging, 24, 1038–1039 (2020).
- Harris P. A. et al.Research electronic data capture (REDCap)-A metadata-driven methodology and workflow process for providing translational research informatics support. Journal of Biomedical Informatics, 42, 377–381 (2009).
- Obeid J. S. et al.Procurement of shared data instruments for research electronic data capture (REDCap). Journal of Biomedical Informatics, 46, 259–265 (2013).
- National Cancer Institute Division of Cancer Control & Population Services. Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). .
- CDC COVID-19 Response Team. Severe outcomes among patients with coronavirus disease 2019 (COVID-19)—United States, February 12–March 16, 2020. Morbidity and mortality weekly report, 69, 343 (2020).
- Saldanha J. et al.Effects of resveratrol supplementation in nrf2 and NF-κB expressions in nondialyzed chronic kidney disease patients: A randomized, double-blind, placebo-controlled, crossover clinical trial. Journal of renal nutrition, 26, 401–406 (2016).
- R Core Team. R: A language and environment for statistical computing (R Foundation for Statistical Computing, 2020).
- StataCorp Stata Statistical Software: Release 17(2021).
- White I., Joseph R. & Best N. A causal modelling framework for reference-based imputation and tipping point analysis in clinical trials with quantitative outcome. Journal of Biopharmaceutical Statistics, 30, 334–350 (2020).
- Walle T. Bioavailability of resveratrol. Annals of the New York Academy of Sciences, 1215, 9–15 (2011).
- Sergides C., Chirilă M., Silvestro L., Pitta D. & Pittas A. Bioavailability and safety study of resveratrol 500 mg tablets in healthy male and female volunteers. Experimental and Therapeutic Medicine, 11, 164–170 (2016).
- Christrup L. Morphine metabolites. Acta Anaesthesiol Scand, 41, 116–122 (1997).
- Centers for Disease Control and Prevention. Influenza Antiviral Medications: Clinician Summary. (2021).
- Bertelli A. et al.Analgesic Resveratrol? Antioxidants & Redox Signaling, 10, 403–404 (2008).
- Rossi Giovanni A., Oliviero S. & Paola C. A. M. Can resveratrol-inhaled formulations be considered potential adjunct treatments for COVID-19? Frontiers in Immunology, 12, 1591 (2021).
Source: PubMed